Stuart Head – General Manager, Gilead Switzerland
With more than 20 years of experience in the pharmaceutical industry and a track record at companies such as MSD, Abbott (later AbbVie), Eisai and AstraZeneca, Stuart Head brings a…
For nearly 30 years, Gilead has led the development of antiviral therapy especially against AIDS and HIV. The availability of HIV therapies has helped avert an estimated 7.8 million AIDS deaths since 2000. Gilead will soon be launching a number of new products in Switzerland, moving into a new era in this domain.
More than 770,000 hepatitis C patients around the world have initiated treatment with a Gilead product since the company introduced its first treatment in late 2013. Today, Sovaldi® is approved in 65 countries and Harvoni®, the first once-daily STR treatment of chronic hepatitis C virus (HCV) infection in genotype 1 patients, is approved in 50 countries.
Contact
Address: Turmstrasse 28, 6300 Zug, Switzerland
Phone: +41 41 580 02 00
With more than 20 years of experience in the pharmaceutical industry and a track record at companies such as MSD, Abbott (later AbbVie), Eisai and AstraZeneca, Stuart Head brings a…
André Lüscher of Gilead Switzerland, reveals how the case of Sovaldi demonstrates the challenges for a healthcare system to handle a truly disruptive medical innovation, the knock-on effect on Gilead´s…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
With the Trump administration imposing tariffs of up to 39 percent on Swiss goods (recently reduced to 15 percent), the pressure on Switzerland’s most influential industrial sector – pharmaceuticals –…
Arturo De la Rosa, Vice President for Latin America at Gilead Sciences, leverages deep regional experience to navigate healthcare challenges and opportunities across multiple countries. He oversees a dual strategy,…
With more than 20 years of experience in the pharmaceutical industry and a track record at companies such as MSD, Abbott (later AbbVie), Eisai and AstraZeneca, Stuart Head brings a…
A roundup of the biggest stories coming out of Germany’s pharma industry, including Bayer’s biggest share price drop in 20 years; Fresenius Kabi’s biosimilar deal with SamChunDang Pharm; Halozyme Therapeutics’…
The lowest spender on healthcare as a percentage of GDP in mainland Latin America. A complex and fragmented reimbursement system. Clinical trial approval delays stretching across eight months. One could…
Gilead’s Mexican affiliate is its largest in the LatAm region, and one that has had an impressive impact as 85 percent of those living with HIV in the country are…
In 2024, people living with HIV have more, and more varied, access to HIV prevention and treatment options than ever before. Thanks to global activism efforts forcing pharma to step…
This year has seen no less than five GM changes at international pharma companies’ Mexican affiliates. Pfizer, MSD, Roche, Sanofi and Gilead have all taken on new local leadership. In…
As a part of the sweeping transformation Saudi Arabia is achieving thanks to its Vision 2030, the Kingdom is also advancing its research ambitions. With the restructuring of its regulatory…
See our Cookie Privacy Policy Here
